A survey of abstracts of high-impact clinical journals indicated most statistical methods presented are summary statisticsTABACK, Nathan; KRZYZANOWSKA, Monika K.Journal of clinical epidemiology. 2008, Vol 61, Num 3, pp 277-281, issn 0895-4356, 5 p.Article

Relationships Between Authorship Contributions and Authors' Industry Financial Ties Among Oncology Clinical TrialsROSE, Susannah L; KRZYZANOWSKA, Monika K; JOFFE, Steven et al.Journal of clinical oncology. 2010, Vol 28, Num 8, pp 1316-1321, issn 0732-183X, 6 p.Article

Factors associated with failure to publish Large randomized trials presented at an Oncology meetingKRZYZANOWSKA, Monika K; PINTILIE, Melania; TANNOCK, Ian F et al.JAMA, the journal of the American Medical Association. 2003, Vol 290, Num 4, pp 495-501, issn 0098-7484, 7 p.Article

Impact of Comorbidity on Chemotherapy Use and Outcomes in Solid Tumors: A Systematic ReviewLEE, Linda; CHEUNG, Winson Y; ATKINSON, Esther et al.Journal of clinical oncology. 2011, Vol 29, Num 1, pp 106-117, issn 0732-183X, 12 p.Article

Disclosure of conflicts of interest by authors of clinical trials and editorials in oncologyRIECHELMANN, Rachel P; LISA WANG; O'CARROLL, Aoife et al.Journal of clinical oncology. 2007, Vol 25, Num 29, pp 4642-4647, issn 0732-183X, 6 p.Article

Treatment of locally advanced pancreatic cancer in the real world: Population-based practices and effectivenessKRZYZANOWSKA, Monika K; WEEKS, Jane C; EARLE, Craig C et al.Journal of clinical oncology. 2003, Vol 21, Num 18, pp 3409-3414, issn 0732-183X, 6 p.Article

Referral Practices of Oncologists to Specialized Palliative CareWENTLANDT, Kirsten; KRZYZANOWSKA, Monika K; SWAMI, Nadia et al.Journal of clinical oncology. 2012, Vol 30, Num 35, pp 4380-4386, issn 0732-183X, 7 p.Article

Quality of abstracts describing randomized trials in the Proceedings of American Society of Clinical Oncology meetings: Guidelines for improved reportingKRZYZANOWSKA, Monika K; PINTILIE, Melania; BREZDEN-MASLEY, Christine et al.Journal of clinical oncology. 2004, Vol 22, Num 10, pp 1993-1999, issn 0732-183X, 7 p.Article

Statistical power of negative randomized controlled trials presented at american society for clinical oncology annual meetingsBEDARD, Philippe L; KRZYZANOWSKA, Monika K; PINTILIE, Melania et al.Journal of clinical oncology. 2007, Vol 25, Num 23, pp 3482-3487, issn 0732-183X, 6 p.Article

Compendium of Unpublished Phase III Trials in Oncology: Characteristics and Impact on Clinical PracticeTAM, Vincent C; TANNOCK, Ian F; MASSEY, Christine et al.Journal of clinical oncology. 2011, Vol 29, Num 23, pp 3133-3139, issn 0732-183X, 7 p.Article

Bereavement Practices of Physicians in Oncology and Palliative CareCHAU, Nicole G; ZIMMERMANN, Camilla; MA, Clement et al.Archives of internal medicine (1960). 2009, Vol 169, Num 10, pp 963-971, issn 0003-9926, 9 p.Article

Impact of Patient Age and Comorbidity on Surgeon Versus Oncologist Preferences for Adjuvant Chemotherapy for Stage III Colon CancerKRZYZANOWSKA, Monika K; REGAN, Meredith M; POWELL, Mark et al.Journal of the American College of Surgeons. 2009, Vol 208, Num 2, pp 202-209, issn 1072-7515, 8 p.Article

Evolution of the Randomized Controlled Trial in Oncology Over Three DecadesBOOTH, Christopher M; CESCON, David W; LISA WANG et al.Journal of clinical oncology. 2008, Vol 26, Num 33, pp 5458-5464, issn 0732-183X, 7 p.Article

Self-Reported Conflicts of Interest of Authors, Trial Sponsorship, and the Interpretation of Editorials and Related Phase III Trials in OncologyBARIANI, Giovanni M; DE CELIS FERRARI, Anezka C. R; HOFF, Paulo M et al.Journal of clinical oncology. 2013, Vol 31, Num 18, pp 2289-2295, issn 0732-183X, 7 p.Article

A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancerRENOUF, Daniel J; WELCH, Stephen; CHEN, Eric et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 5, pp 1339-1344, issn 0344-5704, 6 p.Article

Metastatic Thyroid Carcinoma to the Gastric BodyGOMEZ HERNANDEZ, Karen; HAFEZI-BAKHTIARI, Sara; PIERRE, Andrew et al.The Journal of clinical endocrinology and metabolism. 2014, Vol 99, Num 11, pp 3958-3959, issn 0021-972X, 2 p.Article

Potential drug interactions and duplicate prescriptions among cancer patientsRIECHELMANN, Rachel P; TANNOCK, Ian F; LISA WANG et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 8, pp 592-600, issn 0027-8874, 9 p.Article

Potential Drug Interactions in Cancer Patients Receiving Supportive Care ExclusivelyRIECHELMANN, Rachel P; ZIMMERMANN, Camilla; CHIN, Sheray N et al.Journal of pain and symptom management. 2008, Vol 35, Num 5, pp 535-543, issn 0885-3924, 9 p.Article

A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinomaKRZYZANOWSKA, Monika K; TANNOCK, Ian F; LOCKWOOD, Gina et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 1, pp 135-141, issn 0344-5704, 7 p.Article

Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective studyWALTER, Thomas; HORGAN, Anne M; FELD, Ronald et al.European journal of cancer (1990). 2013, Vol 49, Num 2, pp 329-335, issn 0959-8049, 7 p.Article

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in lodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular ElementsHAYES, D. Neil; LUCAS, Amy S; HOSKINS, Janelle et al.Clinical cancer research (Print). 2012, Vol 18, Num 7, pp 2056-2065, issn 1078-0432, 10 p.Article

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon CancerBENSON, Al B; SCHRAG, Deborah; BROUWERS, Melissa et al.Journal of clinical oncology. 2004, Vol 22, Num 16, pp 3408-3419, issn 0732-183X, 12 p.Article